top of page
gammora.jpg

Code Pharma’s Gammora®: A Breakthrough Toward a Potential HIV Cure

Code Pharma's Gammora® Shows Promising Results in HIV Cure
DE BILT, Netherlands & GLASGOW, Scotland — Code Pharma revealed positive outcomes from an eight-week study of its HIV drug, Gammora®, indicating potential for a cellular-level cure. These groundbreaking results were unveiled at the HIV Drug Therapy 2024 Conference in Glasgow.

gammora.jpg

Promising Results for Gammora® in the Fight Against HIV

Breakthrough in HIV Research: Gammora®'s Positive Findings
Code Pharma announced encouraging results from an eight-week trial of Gammora®, its HIV-treatment drug. Presented at the HIV Drug Therapy 2024 Conference, these findings highlight a potential cure for HIV at the cellular level.

gammora.jpg

Hope on the Horizon: Gammora® Shows Favorable Outcomes Against HIV

Gammora® by Code Pharma: Paving the Way Toward an HIV Cure
Positive eight-week results for Gammora®, Code Pharma’s innovative HIV drug, suggest it may cure the virus at the cellular level. Preliminary data was shared during the HIV Drug Therapy 2024 Conference in Glasgow.

gammora.jpg

Code Pharma Leads the Way: Gammora® Moving Closer to an HIV Cure

Hope for HIV Cure: Code Pharma Shares Promising Gammora® Data
In a groundbreaking announcement, Code Pharma reported positive results from an eight-week study of its HIV drug, Gammora®, showcasing potential for a cellular-level cure. Findings were presented at the 2024 HIV Drug Therapy Conference.

gammora.jpg

Gammora® Achieves Breakthrough Results in HIV Treatment Progress

Code Pharma’s Gammora®: A Step Closer to HIV Eradication
At the HIV Drug Therapy 2024 Conference, Code Pharma unveiled promising eight-week trial results for Gammora®, its HIV drug. The findings suggest a significant advancement toward a cellular-level cure for HIV.

codivit.jpg

Jerusalem Post

This September, we were featured in the Jerusalem Post, Israel’s most read English newspaper. The publication reviews our clinical trials, the promising results, and the impact Codivir may have on the global pandemic. Read the full article here:

222.png

Gulf Today

Read the latest feature of Code Pharma in Gulf Today and find out how Codivir was discovered, our successful Phase I results, and where we stand with the Phase II study and emergency approvals from several countries

Untitled-2.jpg

Global Trend Monitor

We were featured in the Global Trend Monitor, a UAE-based business & lifestyle magazine! 
Read the interview with our founder & CEO
Zyon Ayni and find out how Zyon founded Code Pharma to develop ground-breaking medical solutions as well as the promising results of our clinical trials regarding Codivir, its safety and effectiveness.

covidir.jpg

Press releases

Antiviral drug Codivir shows promising effect against COVID-19

222.png

Code Pharma announces limited fundraising round for internators

We're going for an IPO and are launching a limited fundraising round for professional investors! Please find all the necessary information in our latest press release

Events 

image0.jpeg

10-13 December 2024

Code Pharma presents at the HIV Persistence During Therapy Workshop

taking place at Miami, Florida - USA.
The company will present preliminary results of a clinical trial

 

image1.jpeg

10-13 November 2024

Code Pharma presents at the HIV Drug Therapy 2024 Conference

taking place at Glasgow, Scotland.
The company will present preliminary results of a clinical trial

bottom of page